Amid rising Ebola cases in parts of Africa, researchers at Oxford University and the Serum Institute of India are rapidly advancing development of a new Ebola vaccine targeting the Bundibugyo strain. Unlike the Zaire strain, this Ebola variant currently has no approved vaccine, increasing concern among global public health experts. Scientists involved in the project stated that clinical-grade vaccine doses could be ready within two to three months.
The vaccine uses the ChAdOx platform, the same technology used in the Oxford-AstraZeneca COVID-19 vaccine, allowing researchers to accelerate development using existing safety and manufacturing data. Health officials are closely monitoring outbreaks reported in Uganda, the Democratic Republic of Congo, and neighboring regions. The initiative is supported by global partners including the Coalition for Epidemic Preparedness Innovations…
